Showing 2281-2290 of 3160 results for "".
- Valeant's Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AADhttps://practicaldermatology.com/news/valeants-newly-minted-orthodermatologic-division-makes-a-big-splash-at-summer-aad/2458105/It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch Siliq (brodalumab) for psoriasis and announce their new name change. Dermwire
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi
- Wontech's Pico Laser Gets FDA Nodhttps://practicaldermatology.com/news/wontechs-pico-laser-gets-fda-nod/2458146/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- Senate Unveils Health Care Proposalhttps://practicaldermatology.com/news/senate-unveils-health-care-proposal/2458147/The newly unveiled Senate Republican leadership’s health care proposal, the Better Care Reconciliation Act of 2017, would roll back much of the Affordable Care Act (ACA). According to media reports, the 142-page bill calls for: Elimination of the individual and e
- Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADEhttps://practicaldermatology.com/news/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade/2458177/Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising a
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re